SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-22-017110
Filing Date
2022-06-14
Accepted
2022-06-14 16:01:35
Documents
12
Period of Report
2022-06-14
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K avtx-20220614.htm   iXBRL 8-K 62261
  Complete submission text file 0001628280-22-017110.txt   197870

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT avtx-20220614.xsd EX-101.SCH 1979
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT avtx-20220614_lab.xml EX-101.LAB 24319
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT avtx-20220614_pre.xml EX-101.PRE 12712
6 EXTRACTED XBRL INSTANCE DOCUMENT avtx-20220614_htm.xml XML 10017
Mailing Address 540 GAITHER ROAD SUITE 400 ROCKVILLE MD 20850
Business Address 540 GAITHER ROAD SUITE 400 ROCKVILLE MD 20850 410-522-8707
Avalo Therapeutics, Inc. (Filer) CIK: 0001534120 (see all company filings)

IRS No.: 450705648 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37590 | Film No.: 221014689
SIC: 2834 Pharmaceutical Preparations